Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Drag to rotate
The Eon standard
High Purity Guarantee
Your results are only as good as your compound. Every lot of ARA-290 is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement. Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
ARA-290 is also called cibinetide. It is a peptide made of 11 amino acids, taken from one section of erythropoietin. That is the hormone that drives red blood cell production. ARA-290 was designed to keep signalling at the innate repair receptor while leaving out the red blood cell effect. Research has measured its activity at that receptor, a two-part complex, and examined nerve and inflammation endpoints.
The numbers that define ARA-290 and how it is being studied. For laboratory research use only.
11
Amino Acids
EPO helix-B derived peptide
~2 min
Plasma Half-Life
Short circulating half-life of the peptide
CD131
Co-Receptor Subunit
Acts at the EPOR and CD131 receptor complex
4
Research Areas
Small-Fibre Neuropathy Models
Corneal & Skin Fibre Density
Long-Term Allodynia Thresholds
How It Works
How ARA-290 works
The pathways ARA-290 acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
IRR (EPOR/CD131) Agonism
Innate Repair Receptor
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) - a heterocomplex of the EPO receptor and the β-common receptor (CD131) - without engaging the classical receptor that drives red-cell production.
Selective IRR (EPOR/βcR) agonism
Non-erythropoietic - no effect on hematocrit
Derived from EPO's helix-B surface domain
Resolution of Inflammation
Anti-Inflammatory
Through the innate repair receptor, lower pro-inflammatory signalling and markers of its resolution have been measured, alongside reduced collateral tissue damage in the same models.
Suppresses pro-inflammatory cytokine signaling
Shifts macrophages toward a reparative phenotype
Suppresses spinal microglial activation in pain models
Cytoprotective & Neural Signalling
Survival Signalling
IRR activation engages JAK2/STAT3, PI3K/Akt and anti-apoptotic Bcl-2-family pathways, with cell survival and small-fibre measures recorded despite the peptide's very short plasma half-life.
The main areas ARA-290 is being studied for - and the study-reported figures behind them.
Neuropathic Pain
Sarcoidosis Small-Fiber Neuropathy
ARA 290 is studied in small-fiber neuropathy models, including neuropathic symptom scores and physical-function measures in sarcoidosis research.
Neural Models
Corneal & Skin Nerve Fibre Density
Over a 28-day exposure, neuropathic symptom scores and small-fibre measures were recorded, including corneal nerve fibre density.
Preclinical Pain
Long-Term Allodynia Thresholds
In rodent models, mechanical and cold allodynia thresholds were recorded over 20 weeks alongside spinal microglia response, with an exposure-dependent relationship reported.
Receptor Design
EPO-Derived Cytoprotection
ARA 290 was engineered from EPO's tertiary structure to engage the innate repair receptor selectively, without the erythropoietic activity of native EPO.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
Biological effect duration24-72 h
Plasma half-life~2 min
Effect on red blood cell productionNone
Figures are representative of published research findings and shown for reference.
Molecular Structure
The ARA-290 molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). It was designed to engage the innate repair receptor selectively - without the red-blood-cell-stimulating activity of native EPO.
The IRR is a heterocomplex of the EPO receptor and the β-common receptor (CD131). It is the arm of EPO signalling distinct from the classical homodimeric EPO receptor that controls erythropoiesis. ARA-290 selectively activates it.
No. ARA-290 is non-erythropoietic - it does not engage the receptor pathway that drives red-cell production, so it does not raise hematocrit. That receptor separation is the central rationale behind its design.
ARA 290 is studied in models of small-fiber neuropathy, where the measures examined include neuropathic symptom scores, corneal nerve fiber density and small nerve fiber regrowth. Preclinical models also examine long-term neuropathic pain behaviors.
No. Research-grade ARA-290 sold here is strictly for in vitro laboratory research and analytical applications. It is not a drug and is not intended for human or veterinary use, consumption, or any clinical application.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
